USA flag logo/image

An Official Website of the United States Government

CHEMOENZYMATIC SYNTHESIS OF HEPARIN SULFATE OLIGOSACCARIDES

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
N43CA130050
Solicitation Year:
2013
Solicitation Topic Code:
NCI
Solicitation Number:
Small Business Information
GLYCAN THERAPEUTICS, LLC
GLYCAN THERAPEUTICS, LLC 250 BELL TOWER DR CHAPEL HILL, NC 27599-0001
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: CHEMOENZYMATIC SYNTHESIS OF HEPARIN SULFATE OLIGOSACCARIDES
Agency: HHS
Contract: N43CA130050
Award Amount: $299,447.00
 

Abstract:

The goal of this application is to synthesize heparan sulfate (HS) library consisting of structurally homogeneous oligosaccharides, in response to a SBIR contract call from NCI- 321 Chemically Defined Glycan Libraries . Glycan Therapeutics is a company specializing in the synthesis of structurally diverse HS oligosaccharides. The company is built on an innovative chemoenzymatic method for Glycan synthesis. Polymeric HS contains the disacchariderepeating units of glucuronic or iduronic acid linked to glucosamine that carry sulfo groups. Chemical synthesis of structurally homogeneous HS oligosaccharides is extremely difficult. The chemoenzymatic method reduces synthetic complexity, providing a cost-effective approach to prepare a diverse collection of HSoligosaccharides. A library of 24 oligosaccharides with different sizes and sulfation patterns shall be constructed using this method. The libaray represents the basic structural elements found in naturally occurring HS. Synthesis shall be carried outunder good laboratory practice (GLP) at a scale of 3 mg for each compound, which amount is sufficient for structural analysis by NMR and mass spectrometry as well as the purity analysis by anion-exchange high performance liquid chromatography (HPLC). Four milestones for sample preparations and deliveries are clearly marked. All 24 compounds (50 microgram each) shall be delivered to the NIGMS-designated screen center. PUBLIC HEALTH RELEVANCE

Principal Investigator:

Quin Shi
919-744-4665
QUIN_SHI@UNC.EDU

Business Contact:

Quin Shi
919-744-4665
QUIN_SHI@UNC.EDU
Small Business Information at Submission:

GLYCAN THERAPEUTICS, LLC
GLYCAN THERAPEUTICS, LLC 250 BELL TOWER DR CHAPEL HILL, NC 27599-0001

EIN/Tax ID: 999999999
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No